Specialized Pro-Resolving Mediators from Omega-3 Fatty Acids Improve Amyloid-β Phagocytosis and Regulate Inflammation in Patients with Minor Cognitive Impairment

Journal of Alzheimer's Disease

Volumn 48, Issue 2, 2015, Pages 293-301

  Fiala, Milan ^a   Terrando, Niccolo ^b   Dalli, Jesmond ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Amyloid ; fatty acids; inflammation; mild cognitive impairment; omega 3

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; LEUKOTRIENE; OMEGA 3 FATTY ACID; PROSTAGLANDIN;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BRAIN; CLEARANCE; COGNITIVE DEFECT; DEMENTIA; DIET SUPPLEMENTATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MEDITERRANEAN DIET; NEUROTOXICITY; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; ANIMAL; DIET THERAPY; DIETARY SUPPLEMENT; IMMUNOLOGY; MILD COGNITIVE IMPAIRMENT;

ALZHEIMER DISEASE; ANIMALS; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; MILD COGNITIVE IMPAIRMENT;

EID: 84941271389     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150367     Document Type: Review

References (80)

1. Fiala M, Weitzman R (2015) 1α,25 dihydroxyvitamin D3 and resolvins improve immunity to amyloid-β in patients with Alzheimer's disease. In Diet and nutrition in dementia and cognitive decline, Martin CR, Preedy VR, Eds. Academic Press, London, pp. 701-708.
2. Serhan CN, Petasis NA (2011) Resolvins and protectins in inflammation resolution. Chem Rev 111, 5922-5943.
3. Fiala M, Liu PT, Espinosa-Jeffrey A, Rosenthal MJ, Bernard G, Ringman JM, Sayre J, Zhang L, Zaghi J, Dejbakhsh S, Chiang B, Hui J, Mahanian M, Baghaee A, Hong P, Cashman J (2007) Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc Natl Acad Sci U S A 104, 12849-12854.
4. Avagyan H, Goldenson B, Tse E, Masoumi A, Porter V, Wiedau-Pazos M, Sayre J, Ong R, Mahanian M, Koo P, Bae S, Micic M, Liu PT, Rosenthal MJ, Fiala M (2009) Immune blood biomarkers of Alzheimer disease patients. J Neuroimmunol 210, 67-72.
5. Fiala M, Halder RC, Sagong B, Ross O, Sayre J, Porter V, Bredesen DE (2015) omega-3 Supplementation increases amyloid-beta phagocytosis and resolvin D1 in patients with minor cognitive impairment. FASEB J29, 2681-2689.
6. Feart C, Samieri C, Rondeau V, Amieva H, Portet F, Dartigues JF, Scarmeas N, Barberger-Gateau P (2009) Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. JAMA302, 638-648.
7. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
8. Theendakara V, Patent A, Peters Libeu CA, Philpot B, Flores S, Descamps O, Poksay KS, Zhang Q, Cailing G, Hart M, John V, Rao RV, Bredesen DE (2013) Neuroprotective Sirtuin ratio reversed by ApoE4. Proc Natl Acad Sci U S A 110, 18303-18308.
9. Sadigh-Eteghad S, Sabermarouf B, Majdi A, Talebi M, Farhoudi M, Mahmoudi J (2015) Amyloid-beta: a crucial factor in Alzheimer's disease. Med Princ Pract 24, 1-10.
10. Lauretti E, Di Meco A, Chu J, Pratico D (2015) Modulation of AD neuropathology and memory impairments by the isoprostane F2alpha is mediated by the thromboxane receptor. Neurobiol Aging 36, 812-820.
11. Montine KS, Olson SJ, Amarnath V, Whetsell WO Jr, Graham DG, Montine TJ (1997) Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Am J Pathol 150, 437-443.
12. Zlokovic BV (2013) Cerebrovascular effects of apolipoprotein E: Implications for Alzheimer disease. JAMA Neurol 70, 440-444.
13. Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM (2012) Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Abeta clearance in a mouse model of beta-amyloidosis. Proc Natl Acad Sci U S A 109, 15502-15507.
14. Ladu MJ, Reardon C, Van Eldik L, Fagan AM, Bu G, Holtzman D, Getz GS (2000) Lipoproteins in the central nervous system. Ann N Y Acad Sci 903, 167-175.
15. Zolezzi JM, Bastias-Candia S, Santos MJ, Inestrosa NC (2014) Alzheimer's disease: Relevant molecular and physiopathological events affecting amyloid-beta brain balance and the putative role of PPARs. Front Aging Neurosci 6, 176.
16. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE (2012) ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 335, 1503-1506.
17. Landreth GE, Cramer PE, Lakner MM, Cirrito JR, Wesson DW, Brunden KR, Wilson DA (2013) Response to comments on "ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models". Science 340, 924-g.
18. Mandrekar-Colucci S, Karlo JC, Landreth GE (2012) Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci 32, 10117-10128.
19. Li X, Melief E, Postupna N, Montine KS, Keene CD, Montine TJ (2015) Prostaglandin E receptor subtype 2 regulation of scavenger receptor CD36 modulates microglial Abeta phagocytosis. Am J Pathol 185, 230-239.
20. Huttenrauch M, Baches S, Gerth J, Bayer TA, Weggen S, Wirths O (2015) Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFADmouse model of Alzheimer's disease. J Alzheimers Dis 44, 1291-1302.
21. Miners JS, Baig S, Palmer J, Palmer LE, Kehoe PG, Love S (2008) Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol 18, 240-252.
22. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, Lopez CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W, Tompkins RG, Inflammation, Host Response to Injury, Large Scale Collaborative Research, Program (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 110, 3507-3512.
23. Kokjohn TA, Roher AE (2009) Amyloid precursor protein transgenic mouse models and Alzheimer's disease: Understanding the paradigms, limitations, and contributions. Alzheimers Dement 5, 340-347.
24. Netea MG, Wijmenga C, O'Neill LA (2012) Genetic variation in Toll-like receptors and disease susceptibility. Nat Immunol 13, 535-542.
25. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330, 1774.
26. Hickman SE, El Khoury J (2010) Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease. CNS Neurol Disord Drug Targets 9, 168-173.
27. Persidsky Y, Ghorpade A, Rasmussen J, Limoges J, Liu XJ, Stins M, Fiala M, Way D, Kim KS, Witte MH, Weinand M, Carhart L, Gendelman HE (1999) Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. Am J Pathol 155, 1599-1611.
28. Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, Graves MC, Vinters HV (2002) Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the bloodbrain barrier. Eur J Clin Invest 32, 360-371.
29. Majerova P, Zilkova M, Kazmerova Z, Kovac A, Paholikova K, Kovacech B, Zilka N, Novak M (2014) Microglia display modest phagocytic capacity for extracellular tau oligomers. J Neuroinflammation 11, 161.
30. Yu Y, Ye RD (2015) Microglial abeta receptors in Alzheimer's disease. Cell Mol Neurobiol 35, 71-83.
31. Landreth GE, Reed-Geaghan EG (2009) Toll-like receptors in Alzheimer's disease. Curr Top Microbiol Immunol 336, 137-153.
32. Cudaback E, Jorstad NL, Yang Y, Montine TJ, Keene CD (2014) Therapeutic implications of the prostaglandin pathway in Alzheimer's disease. Biochem Pharmacol 88, 565-572.
33. Guerreiro R, Hardy J (2013) TREM2 and neurodegenerative disease. N Engl J Med 369, 1569-1570.
34. Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M (2006) Cutting edge: TREM-2 attenuates macrophage activation. J Immunol 177, 3520-3524.
35. Lorton D, Kocsis JM, King L, Madden K, Brunden KR (1996) beta-Amyloid induces increased release of interleukin-1 beta from lipopolysaccharide-activated human monocytes. J Neuroimmunol 67, 21-29.
36. Mizwicki MT, Liu G, Fiala M, Magpantay L, Sayre J, Siani A, Mahanian M, Weitzman R, Hayden EY, Rosenthal MJ, Nemere I, Ringman J, Teplow DB (2013) 1alpha,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-beta phagocytosis and inflammation in Alzheimer's disease patients. J Alzheimers Dis 34, 155-170.
37. Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN (2007) Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 178, 3912-3917.
38. Doens D, Fernandez PL (2014) Microglia receptors and their implications in the response to amyloid beta for Alzheimer's disease pathogenesis. J Neuroinflammation 11, 48.
39. Fassbender K, Walter S, Kuhl S, Landmann R, Ishii K, Bertsch T, Stalder AK, Muehlhauser F, Liu Y, Ulmer AJ, Rivest S, Lentschat A, Gulbins E, Jucker M, Staufenbiel M, Brechtel K, Walter J, Multhaup G, Penke B, Adachi Y, Hartmann T, Beyreuther K (2004) The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J18, 203-205.
40. Fiala M, Lin J, Ringman J, Kermani-Arab V, Tsao G, Patel A, Lossinsky AS, Graves MC, Gustavson A, Sayre J, Sofroni E, Suarez T, Chiappelli F, Bernard G (2005) Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J Alzheimers Dis 7, 221-232; discussion 255-262.
41. Fiala M, Cribbs DH, Rosenthal M, Bernard G (2007) Phagocytosis of amyloid-beta and inflammation: Two faces of innate immunity in Alzheimer's disease. J Alzheimers Dis 11, 457-463.
42. Zaghi J, Goldenson B, Inayathullah M, Lossinsky AS, Masoumi A, Avagyan H, Mahanian M, Bernas M, Weinand M, Rosenthal MJ, Espinosa-Jeffrey A, de Vellis J, Teplow DB, Fiala M (2009) Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. Acta Neuropathol 117, 111-124.
43. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study:Arandomized double-blind trial. Arch Neurol 63, 1402-1408.
44. Samuelsson B (2012) Role of basic science in the development of new medicines: Examples from the eicosanoid field. J Biol Chem 287, 10070-10080.
45. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K (2000) Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192, 1197-1204.
46. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) Lipid mediator class switching during acute inflammation: Signals in resolution. Nat Immunol 2, 612-619.
47. Serhan CN (2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92-101.
48. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN (2003) Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 278, 14677-14687.
49. Marcheselli VL, Hong S, Lukiw WJ, Tian XH, Gronert K, Musto A, Hardy M, Gimenez JM, Chiang N, Serhan CN, Bazan NG (2003) Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 278, 43807-43817.
50. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG (2004) Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A 101, 8491-8496.
51. Bazan NG, Molina MF, Gordon WC (2011) Docosahexaenoic Acid signalolipidomics in nutrition: Significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. Annu Rev Nutr 31, 321-351.
52. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) Lipid mediator class switching during acute inflammation: Signals in resolution. Nat Immunol 2, 612-619.
53. Serhan CN, Dalli J, Colas RA, Winkler JW, Chiang N (2015) Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochim Biophys Acta 1851, 397-413.
54. Serhan CN, Chiang N, Dalli J (2015) The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin Immunol, doi: 10.1016/j.smim.2015.03.004
55. Serhan CN, Chiang N, Van Dyke TE (2008) Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8, 349-361.
56. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, Petasis NA, Serhan CN (2010) Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A 107, 1660-1665.
57. Terrando N, Gomez-Galan M, Yang T, Carlstrom M, Gustavsson D, Harding RE, Lindskog M, Eriksson LI (2013) Aspirin-triggered resolvin D1 prevents surgery-induced cognitive decline. FASEB J27, 3564-3571.
58. Serhan CN, Dalli J, Karamnov S, Choi A, Park CK, Xu ZZ, Ji RR, Zhu M, Petasis NA (2012) Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J26, 1755-1765.
59. Dalli J, Chiang N, Serhan CN (2014) Identification of 14-series sulfido-conjugated mediators that promote resolution of infection and organ protection. Proc Natl Acad Sci U S A 111, E4753-E4761.
60. Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN (2014) Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am J Physiol Cell Physiol 307, C39-C54.
61. Dalli J, Kraft BD, Colas RA, Shinohara M, Fredenburgh LE, Hess DR, Chiang N, Welty-Wolf KE, Choi AM, Piantadosi CA, Serhan CN (2015) Proresolving lipid mediator profiles in baboon pneumonia are regulated by inhaled carbon monoxide. Am J Respir Cell Mol Biol, doi: 10.1165/rcmb.2014-0299OC.
62. Serhan CN, Dalli J, Karamnov S, Choi A, Park CK, Xu ZZ, Ji RR, Zhu M, Petasis NA (2012) Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J26, 1755-1765.
63. Gordon S, Mantovani A (2011) Diversity and plasticity of mononuclear phagocytes. Eur J Immunol 41, 2470-2472.
64. Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, Helft J, Chow A, Elpek KG, Gordonov S, Mazloom AR, Ma'ayan A, Chua WJ, Hansen TH, Turley SJ, Merad M, Randolph GJ, Immunological Genome C (2012) Geneexpression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol 13, 1118-1128.
65. Stables MJ, Shah S, Camon EB, Lovering RC, Newson J, Bystrom J, Farrow S, Gilroy DW (2011) Transcriptomic analyses of murine resolution-phase macrophages. Blood 118, e192-e208.
66. Schif-Zuck S, Gross N, Assi S, Rostoker R, Serhan CN, Ariel A (2011) Saturated-efferocytosis generates pro-resolving CD11b low macrophages: Modulation by resolvins and glucocorticoids. Eur J Immunol 41, 366-379.
67. Titos E, Rius B, Gonzalez-Periz A, Lopez-Vicario C, Moran-Salvador E, Martinez-Clemente M, Arroyo V, Claria J (2011) Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J Immunol 187, 5408-5418.
68. Hellmann J, Tang Y, Kosuri M, Bhatnagar A, Spite M (2011) Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J25, 2399-2407.
69. Dalli J, Zhu M, Vlasenko NA, Deng B, Haeggstrom JZ, Petasis NA, Serhan CN (2013) The novel 13S,14S-epoxymaresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J27, 2573-2583.
70. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R, Alzheimer's Disease Cooperative Study Steering Committee, Solanezumab Study Group (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 370, 311-321.
71. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG (2005) A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 115, 2774-2783.
72. Eckenhoff RG, Laudansky KF (2013) Anesthesia, surgery, illness and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 47, 162-166.
73. Berger M, Burke J, Eckenhoff R, Mathew J (2014) Alzheimer's disease, anesthesia, and surgery: A clinically focused review. J Cardiothorac Vasc Anesth 28, 1609-1623.
74. Zhang B, Tian M, Zheng H, Zhen Y, Yue Y, Li T, Li S, Marcantonio ER, Xie Z (2013) Effects of anesthetic isoflurane and desflurane on human cerebrospinal fluid Abeta and tau level. Anesthesiology 119, 52-60.
75. Chiang N, Schwab JM, Fredman G, Kasuga K, Gelman S, Serhan CN (2008) Anesthetics impact the resolution of inflammation. PLoS One 3, e1879.
76. Mas E, Croft KD, Zahra P, Barden A, Mori TA (2012) Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin Chem 58, 1476-1484.
77. Barden A, Mas E, Croft KD, Phillips M, Mori TA (2014) Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation. J Lipid Res 55, 2401-2407.
78. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N (2010) A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 68, 930-941.
79. Fiala M (2015) Curcumin and omega-3 fatty acids enhance NK cell-induced apoptosis of pancreatic cancer cells but curcumin inhibits interferon-gamma production: Benefits of omega-3 with curcumin against cancer. Molecules 20, 3020-3026.
80. Barberger-Gateau P, Samieri C, Feart C, Plourde M (2011) Dietary omega 3 polyunsaturated fatty acids and Alzheimer's disease: Interaction with apolipoprotein E genotype. Curr Alzheimer Res 8, 479-491.